Subject:
- Active Substance: Tralokinumab
- Name: Adtralza®
- Therapeutic area: Atopic dermatitis
- Pharmaceutical company: LEO Pharma GmbH
Time table:
- Start: 15.11.2022
- Publication of assessment: 15.02.2023
- End of public hearing: 09.03.2023
- Final decision by G-BA: middle of May 2023
Comparative therapy:
- Dupilumab (if applicable, in combination with topical corticosteroids and/or topical calcineurin inhibitors)